Clinical Trial Update: Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of the everolimus-eluting Xience V stent for treating in-stent restenosis of a bare-metal stent, with two-year …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Restenosis

Drugs mentioned

• Everolimus (everolimus)
• Xience V stent (everolimus-eluting)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Restenosis | Phase 3 | Status: COMPLETED